drugset / Trial / NCT06880549
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
Timeline
- Start
- 2025-03-25
- Primary completion
- 2027-08-03
- Completion
- 2027-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mRNA-4106 | Unknown | — | Intramuscular |
| Subject | mRNA-4200 | Unknown | — | Intramuscular |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |